Featured Tickers:
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Protagonist Therapeutics, Inc. or Aurinia Pharmaceuticals Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.
Read on to learn how Protagonist Therapeutics, Inc. and Aurinia Pharmaceuticals Inc. compare based on key financial metrics to determine which better meets your investment needs.
About Protagonist Therapeutics, Inc. and Aurinia Pharmaceuticals Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company that engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs. It offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. The company also develops AUR200, a dual inhibitor of B cell activating factor and a proliferation inducing ligand for the potential treatment of autoimmune diseases. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
Latest Biotechnology and Protagonist Therapeutics, Inc., Aurinia Pharmaceuticals Inc. Stock News
As of November 20, 2025, Protagonist Therapeutics, Inc. had a $5.3 billion market capitalization, compared to the Biotechnology median of $193.4 million. Protagonist Therapeutics, Inc.’s stock is NA in 2025, NA in the previous five trading days and up 108.38% in the past year.
Currently, Protagonist Therapeutics, Inc.’s price-earnings ratio is 116.9. Protagonist Therapeutics, Inc.’s trailing 12-month revenue is $209.2 million with a 21.9% net profit margin. Year-over-year quarterly sales growth most recently was 0.0%. Analysts expect adjusted earnings to reach $-1.871 per share for the current fiscal year. Protagonist Therapeutics, Inc. does not currently pay a dividend.
Currently, Aurinia Pharmaceuticals Inc.’s price-earnings ratio is 27.5. Aurinia Pharmaceuticals Inc.’s trailing 12-month revenue is $265.8 million with a 29.3% net profit margin. Year-over-year quarterly sales growth most recently was 8.4%. Analysts expect adjusted earnings to reach $0.782 per share for the current fiscal year. Aurinia Pharmaceuticals Inc. does not currently pay a dividend.
How We Compare Protagonist Therapeutics, Inc. and Aurinia Pharmaceuticals Inc. Stock Grades
Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.
AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Protagonist Therapeutics, Inc. and Aurinia Pharmaceuticals Inc.’s stock grades to see how they measure up against one another.
Learn more about A+ Investor here!
Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions